Acute Leukemia Perspective

 
 
  • Today's Cancer Research Pioneers More than 50 years after the introduction of chemotherapy, a new wave of researchers seek to radically advance cancer treatments.
  • Perils and Pluses of 'Compassionate Use'   When a person is dying, there may be lots of pressure to give access to drugs still in development. This happened during the recent Ebola outbreak. But there are serious pros and cons to doing this.
  • Telling Stories: Why I Went Into Oncology An oncology fellow at Duke University describes why she chose the field and discusses whether the reality lives up to her expectations.
  • The Year in Hematologic Malignancies Experts in hematologic malignancies comment on the most important developments and practice-changing clinical trials of 2014.
  • Have We Overlooked Palliative Care?   Palliative care is not just for patients in hospice, explains Dr. Diane Meier; good palliative care can help relieve the suffering of people with chronic or disabling illnesses.
  • CAR T Cells: A Look Under the Hood and Down the Road Lost your way in immunotherapy? Dr. Mark Adler provides clinicians a roadmap for navigating cancer immunotherapy and takes one of the most promising approaches -- CAR T cells -- for a test drive.
  • ASCO President on the Triumph of the Open Mind   Dr. James Holland, president of ASCO in 1976-1977, talks to Dr. Kathy Miller about the early days of oncology, the society, and the humanist passion that is a driving force for both.
  • Ancestry Data in Cancer: Predictive, Prognostic, or Both?   Dr. Maurie Markman considers how genetic ancestry data might be used to predict risk for cancer relapse and inform potential ways to mitigate that risk.
  • Off and On Again Story of Ponatinib in CML Dr. Michael Deininger reviews data from ASH 2013 on ponatinib in chronic myeloid leukemia, and discusses the drug's future in view of the recent FDA decision to suspend -- and reinstate -- approval.
  • Is Obinutuzumab the Drug to Watch in CLL? Drs. Cheson and Czuczman highlight data on obinutuzumab, ibrutinib, idelalisib, and emerging agents that are reshaping the leukemia and lymphoma landscape.
  • Top News From ASH 2013: Slideshow Highlights include new promise with CAR-engineered T-cells for leukemia and lymphoma, a potentially disease-modifying drug for myelofibrosis, and novel targeted therapies for CLL.
  • Risk for Leukemia After Breast Cancer A new study shows that younger women had the highest risk for myelodysplasia or acute myeloid leukemia after a diagnosis of breast cancer.
  • 18th Congress of the European Hematology Association (EHA) Read clinically focused news coverage of key developments from EHA 2013.
  • New Therapy Unleashes 'Serial Killer' Cells in Leukemia Adoptive immunotherapy is providing exciting preliminary results in leukemia patients. Leading researcher Dr. Carl June explains the therapy and its potential application to other cancers.
  • ALL: Exciting New Therapy   CART offers promise even for children with the most refractory disease.
  • Top News From ASH 2012: Slideshow Highlights include that chemo is not necessary for APL, the debate about platelet transfusions in patients with hematologic malignancies is still unresolved, and quizartinib has unprecedented activity in relapsed AML.
  • Bortezomib Combo Keeps on Giving in Myeloma   Dr. Martin Dreyling highlights presentations in blood cancers at ESMO 2012, including important findings on bortezomib, combinations of prognostic markers, and ways to deliver personalized treatment.
  • Can Genetics Predict Chemo Dose Response in AML?   Genetic profiling is used in patients with acute myeloid leukemia to predict prognosis. Dr. Maurie Markman looks at how it can also be used to predict response to chemotherapy.
  • Blood Cancers: What to Look for in Leukemia   Dr. Bruce Cheson highlights noteworthy studies, new drugs, and impressive data in ALL, CLL, and CML that will be discussed at ASCO® 2012.
  • Crossing Boundaries in Molecular Therapy: HER2 in ALL   Looking at a recent report describing the use of trastuzumab in HER2-positive ALL, Dr. Maurie Markman considers what this means for the future of molecular-targeted cancer therapy.